Symbols / IKT
IKT Chart
About
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 248.60M |
| Enterprise Value | 108.59M | Income | -47.66M | Sales | — |
| Book/sh | 0.81 | Cash/sh | 0.85 | Dividend Yield | — |
| Payout | 0.00% | Employees | 15 | IPO | — |
| P/E | 4.36 | Forward P/E | -8.20 | PEG | — |
| P/S | — | P/B | 2.54 | P/C | — |
| EV/EBITDA | -2.05 | EV/Sales | — | Quick Ratio | 11.55 |
| Current Ratio | 11.73 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 0.47 | EPS next Y | -0.25 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 | ROA | -79.11% |
| ROE | -131.71% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 121.27M |
| Shs Float | 43.65M | Short Float | 11.49% | Short Ratio | 17.28 |
| Short Interest | — | 52W High | 2.89 | 52W Low | 1.33 |
| Beta | 0.84 | Avg Volume | 608.61K | Volume | 3.99M |
| Target Price | $6.00 | Recom | Strong_buy | Prev Close | $1.80 |
| Price | $2.05 | Change | 13.89% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.00
Mean price target
2. Current target
$2.05
Latest analyst target
3. DCF / Fair value
$-1.96
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.05
Low
$3.00
High
$8.00
Mean
$6.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-21 | init | B of A Securities | — → Buy | $6 |
| 2025-12-11 | init | Cantor Fitzgerald | — → Overweight | $4 |
| 2025-03-28 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-12 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-11-08 | init | Jefferies | — → Buy | $8 |
| 2024-10-14 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-08-16 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-05-21 | main | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2024-03-05 | main | HC Wainwright & Co. | Buy → Buy | $27 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2023-06-30 | main | HC Wainwright & Co. | Buy → Buy | $27 |
News
RSS: Latest IKT news- Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Lifesci Capital to "Strong-Buy" Rating - MarketBeat Wed, 25 Feb 2026 11
- $IKT stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 23 Feb 2026 14
- IKT Stock Bounces Amid Steady Growth Potential - StocksToTrade Mon, 23 Feb 2026 17
- Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance Sun, 22 Feb 2026 11
- Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001 - TipRanks ue, 24 Feb 2026 16
- Inhibikase Therapeutics Stock Faces Challenges Amid Financial Uncertainty - timothysykes.com Mon, 23 Feb 2026 14
- IKT Surges Amid Strategic Developments and Market Shifts - StocksToTrade Mon, 23 Feb 2026 15
- Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire hu, 20 Nov 2025 08
- While institutions invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) benefited from last week's 11% gain, individual investors stood to gain the most - simplywall.st ue, 16 Dec 2025 08
- Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH - Seeking Alpha Fri, 02 May 2025 07
- B of A Securities Initiates Coverage of Inhibikase Therapeutics (IKT) with Buy Recommendation - Nasdaq Wed, 21 Jan 2026 08
- Inhibikase Therapeutics stock falls after announcing public offering - Investing.com hu, 20 Nov 2025 08
- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat Sun, 15 Feb 2026 08
- Inhibikase Therapeutics: A Surge in Market Interest on Recent Developments - timothysykes.com Mon, 23 Feb 2026 16
- Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire hu, 20 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2068965 | 2999999 | — | Purchase at price 1.45 per share. | SANDS CAPITAL LIFE SCIENCES PULSE FUND II, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-21 00:00:00 | D |
| 1 | 57265 | — | — | Stock Award(Grant) at price 0.00 per share. | MUNSHI AMIT D | Director | — | 2025-02-21 00:00:00 | D |
| 2 | 365000 | 810300 | — | Purchase at price 2.22 per share. | MUNSHI AMIT D | Director | — | 2024-10-21 00:00:00 | I |
| 3 | 145000 | 321900 | — | Purchase at price 2.22 per share. | KUSH ARVIND | Director | — | 2024-10-21 00:00:00 | D |
| 4 | 1460000 | 3241200 | — | Purchase at price 2.22 per share. | BELLINI ROBERTO | Director | — | 2024-10-21 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -28.56M | -19.91M | -18.12M | -14.77M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -27.52M | -19.03M | -18.05M | -14.79M |
| ReconciledDepreciation | 26.27K | 177.40K | 6.72K | 0.00 |
| EBITDA | -28.56M | -19.91M | -18.12M | -14.77M |
| EBIT | -28.59M | -20.09M | -18.13M | -14.77M |
| NetInterestIncome | 1.07M | 1.06M | 74.45K | -19.92K |
| InterestExpense | 19.92K | |||
| InterestIncome | 1.07M | 1.06M | 74.45K | |
| NormalizedIncome | -27.52M | -19.03M | -18.05M | -14.79M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -27.52M | -19.03M | -18.05M | -14.79M |
| TotalExpenses | 28.59M | 20.09M | 18.13M | 14.77M |
| TotalOperatingIncomeAsReported | -28.59M | -20.09M | -18.13M | -14.77M |
| DilutedAverageShares | 23.71M | 6.03M | 4.22M | 3.03M |
| BasicAverageShares | 23.71M | 6.03M | 4.22M | 3.03M |
| DilutedEPS | -1.16 | -3.16 | -4.28 | -4.86 |
| BasicEPS | -1.16 | -3.16 | -4.28 | -4.86 |
| DilutedNIAvailtoComStockholders | -27.52M | -19.03M | -18.05M | -14.79M |
| NetIncomeCommonStockholders | -27.52M | -19.03M | -18.05M | -14.79M |
| NetIncome | -27.52M | -19.03M | -18.05M | -14.79M |
| NetIncomeIncludingNoncontrollingInterests | -27.52M | -19.03M | -18.05M | -14.79M |
| NetIncomeContinuousOperations | -27.52M | -19.03M | -18.05M | -14.79M |
| PretaxIncome | -27.52M | -19.03M | -18.05M | -14.79M |
| NetNonOperatingInterestIncomeExpense | 1.07M | 1.06M | 74.45K | -19.92K |
| InterestExpenseNonOperating | 19.92K | |||
| InterestIncomeNonOperating | 1.07M | 1.06M | 74.45K | |
| OperatingIncome | -28.59M | -20.09M | -18.13M | -14.77M |
| OperatingExpense | 28.59M | 20.09M | 18.13M | 14.77M |
| OtherOperatingExpenses | -260.50K | -123.44K | -3.10M | |
| ResearchAndDevelopment | 17.21M | 13.62M | 12.03M | 11.36M |
| SellingGeneralAndAdministration | 11.38M | 6.73M | 6.22M | 6.51M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 69.36M | 6.19M | 4.20M | 4.19M |
| ShareIssued | 69.36M | 6.19M | 4.20M | 4.19M |
| TotalDebt | 110.52K | 240.22K | 351.29K | 248.91K |
| TangibleBookValue | 94.87M | 10.98M | 21.04M | 38.42M |
| InvestedCapital | 94.87M | 10.98M | 21.04M | 38.66M |
| WorkingCapital | 94.72M | 10.77M | 20.68M | 38.42M |
| NetTangibleAssets | 94.87M | 10.98M | 21.04M | 38.42M |
| CapitalLeaseObligations | 110.52K | 240.22K | 351.29K | 0.00 |
| CommonStockEquity | 94.87M | 10.98M | 21.04M | 38.42M |
| TotalCapitalization | 94.87M | 10.98M | 21.04M | 38.42M |
| TotalEquityGrossMinorityInterest | 94.87M | 10.98M | 21.04M | 38.42M |
| StockholdersEquity | 94.87M | 10.98M | 21.04M | 38.42M |
| GainsLossesNotAffectingRetainedEarnings | -37.25K | 877.00 | 104.72K | 0.00 |
| OtherEquityAdjustments | -37.25K | 877.00 | 104.72K | |
| RetainedEarnings | -94.42M | -66.90M | -47.87M | -29.82M |
| AdditionalPaidInCapital | 189.25M | 77.87M | 68.80M | 68.21M |
| CapitalStock | 69.36K | 6.19K | 4.22K | 25.16K |
| CommonStock | 69.36K | 6.19K | 4.22K | 25.16K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.73M | 3.53M | 3.90M | 4.05M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 90.12K | 205.45K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 90.12K | 205.45K | 0.00 |
| LongTermCapitalLeaseObligation | 0.00 | 90.12K | 205.45K | 0.00 |
| CurrentLiabilities | 3.73M | 3.44M | 3.70M | 4.05M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 110.52K | 150.09K | 145.84K | 248.91K |
| CurrentCapitalLeaseObligation | 110.52K | 150.09K | 145.84K | 0.00 |
| CurrentDebt | 248.91K | |||
| OtherCurrentBorrowings | 248.91K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 999.30K | 635.45K | 460.00K | 421.73K |
| PayablesAndAccruedExpenses | 2.62M | 2.65M | 3.09M | 3.38M |
| CurrentAccruedExpenses | 1.68M | 1.62M | 1.94M | 2.29M |
| InterestPayable | 0.00 | 968.00 | ||
| Payables | 943.02K | 1.03M | 1.15M | 1.09M |
| OtherPayable | 381.78K | |||
| AccountsPayable | 943.02K | 646.77K | 1.15M | 1.09M |
| TotalAssets | 98.60M | 14.51M | 24.94M | 42.47M |
| TotalNonCurrentAssets | 148.54K | 295.60K | 565.17K | 0.00 |
| NetPPE | 148.54K | 295.60K | 565.17K | 0.00 |
| AccumulatedDepreciation | -56.73K | -30.45K | -6.72K | |
| GrossPPE | 205.26K | 326.05K | 571.90K | 0.00 |
| OtherProperties | 16.89K | 153.67K | ||
| MachineryFurnitureEquipment | 103.83K | 103.83K | 89.59K | |
| BuildingsAndImprovements | 101.44K | 222.23K | 328.64K | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 98.45M | 14.21M | 24.37M | 42.47M |
| OtherCurrentAssets | 826.47K | 739.18K | 163.45K | 1.50M |
| PrepaidAssets | 81.31K | 219.82K | 1.12M | 107.00K |
| Receivables | 0.00 | 39.88K | 110.14K | |
| AccountsReceivable | 0.00 | 39.88K | 110.14K | |
| CashCashEquivalentsAndShortTermInvestments | 97.54M | 13.25M | 23.05M | 40.75M |
| OtherShortTermInvestments | 41.05M | 4.09M | 15.86M | 0.00 |
| CashAndCashEquivalents | 56.49M | 9.17M | 7.19M | 40.75M |
| CashFinancial | 7.19M | 40.75M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -19.15M | -18.10M | -17.59M | -14.30M |
| RepaymentOfDebt | 0.00 | -248.91K | -42.53K | |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 103.48M | 8.54M | 0.00 | 41.14M |
| CapitalExpenditure | -14.24K | -243.25K | ||
| InterestPaidSupplementalData | 0.00 | 973.00 | 1.15K | |
| EndCashPosition | 56.49M | 9.17M | 7.19M | 40.75M |
| BeginningCashPosition | 9.17M | 7.19M | 40.75M | 13.95M |
| ChangesInCash | 47.33M | 1.98M | -33.56M | 26.80M |
| FinancingCashFlow | 103.48M | 8.41M | -204.77K | 41.09M |
| CashFlowFromContinuingFinancingActivities | 103.48M | 8.41M | -204.77K | 41.09M |
| NetOtherFinancingCharges | -138.56K | -77.65K | ||
| ProceedsFromStockOptionExercised | 0.00 | 44.14K | 78.50K | |
| NetCommonStockIssuance | 103.48M | 8.54M | 0.00 | 41.14M |
| CommonStockIssuance | 103.48M | 8.54M | 0.00 | 41.14M |
| NetIssuancePaymentsOfDebt | 0.00 | -248.91K | -42.53K | |
| NetShortTermDebtIssuance | 0.00 | -248.91K | -42.53K | |
| ShortTermDebtPayments | 0.00 | -248.91K | -42.53K | |
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | -42.53K | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -37.00M | 11.66M | -16.01M | 0.00 |
| CashFlowFromContinuingInvestingActivities | -37.00M | 11.66M | -16.01M | 0.00 |
| NetInvestmentPurchaseAndSale | -37.00M | 11.67M | -15.76M | 0.00 |
| SaleOfInvestment | 23.45M | 41.10M | 4.96M | 0.00 |
| PurchaseOfInvestment | -60.46M | -29.43M | -20.73M | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | -14.24K | -243.25K | 0.00 |
| PurchaseOfPPE | 0.00 | -14.24K | -243.25K | 0.00 |
| OperatingCashFlow | -19.15M | -18.09M | -17.35M | -14.30M |
| CashFlowFromContinuingOperatingActivities | -19.15M | -18.09M | -17.35M | -14.30M |
| ChangeInWorkingCapital | 204.93K | 234.76K | 171.18K | -1.76M |
| ChangeInOtherWorkingCapital | 38.05K | -2.33M | ||
| ChangeInOtherCurrentLiabilities | -129.70K | -111.07K | -9.86K | |
| ChangeInOtherCurrentAssets | 120.79K | 106.42K | 38.05K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 691.86K | -642.89K | -255.93K | 1.45M |
| ChangeInAccruedExpense | 420.07K | -138.48K | -317.32K | 2.08M |
| ChangeInPayable | 271.78K | -504.41K | 61.40K | -630.90K |
| ChangeInAccountPayable | 271.78K | -504.41K | 61.40K | -630.90K |
| ChangeInPrepaidAssets | -478.01K | 842.42K | 328.66K | -780.53K |
| ChangeInReceivables | 0.00 | 39.88K | 70.26K | -110.14K |
| ChangesInAccountReceivables | 0.00 | 39.88K | 70.26K | -110.14K |
| OtherNonCashItems | 31.54K | 67.00K | 32.84K | |
| StockBasedCompensation | 8.14M | 500.15K | 458.15K | 1.53M |
| DepreciationAmortizationDepletion | 26.27K | 177.40K | 6.72K | 0.00 |
| DepreciationAndAmortization | 26.27K | 177.40K | 6.72K | 0.00 |
| Depreciation | 26.27K | 177.40K | 6.72K | 0.00 |
| OperatingGainsLosses | 688.78K | |||
| GainLossOnInvestmentSecurities | 688.78K | |||
| NetIncomeFromContinuingOperations | -27.52M | -19.03M | -18.05M | -14.79M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IKT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|